{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_28", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-2 16:30:0", "close_timestamp": 1638462600283, "created": "02/12/2021 16:29:59", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-12-02", "gender": "female", "id": "001c7f70-5e2a-4dd0-9fb8-631e81fabb64", "open_date_time": "2021-11-2 16:20:42", "open_timestamp": 1638462042465, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "A study has shown that an existing, anti-parasitic approved treatment is effective at killing COVID-19 within 48 hours. ", "task_condition": "text", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 557818, "what": "COVID-19, Ivermectin, COVID-19 treatment", "when_happened": "few_years_ago", "where_location": "Melbourne, Australia", "who": "BDI, Doherty Institute, Dr Kylie Wagstaff", "why": "Breakthrough in treatment during global pandemic, already globally available so can help people sooner than the vaccine rollout will"}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_28", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-2 16:48:25", "close_timestamp": 1638463705649, "created": "02/12/2021 16:48:25", "department": "Computing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-12-02", "gender": "female", "id": "5950d73c-c2d2-4fda-87ca-a5921a62690c", "open_date_time": "2021-11-2 16:38:41", "open_timestamp": 1638463121231, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "Reports on the progress of the Novavax vaccine rollout in the US. Discusses information surrounding how many doses are needed, how many of the population have already been vaccinated etc as well as challenges faced including new strains of the virus.", "task_condition": "viz", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 584418, "what": "The Novavax vaccine rollout in the US, how much of the population are being vaccinated, challenges faced including new strains of the virus whose resistance to the vaccine is unknown", "when_happened": "current_month", "where_location": "United States of America", "who": "Novavax", "why": "Discusses information important to a large population of people, centres around healthcare and the curing of a global pandemic responsible for millions of deaths"}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_28", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-2 16:38:33", "close_timestamp": 1638463113035, "created": "02/12/2021 16:38:32", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-12-02", "gender": "female", "id": "985b7d75-e54a-4d50-b6d8-a432873ec60a", "open_date_time": "2021-11-2 16:30:9", "open_timestamp": 1638462609584, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "Professor Thomas Borody expresses anger at the delay of rolling out his viral treatment method which he cites as having an almost 100% cure rate. Borody believes instructing GPs to issue this treatment to people suffering from COVID-19 would greatly increase the country's chance of beating the virus.", "task_condition": "text", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 503451, "what": "Professor Thomas Borody imploring Australia's Government to roll out a method of treating COVID-19 which he believes will eradicate the virus safely", "when_happened": "few_years_ago", "where_location": "Sydney, Australia", "who": "Thomas Borody", "why": "Relevant based on current global events, potential breakthrough in the treatment of COVID-19, briefly mentions another potential treatment"}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_28", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-2 16:54:0", "close_timestamp": 1638464040681, "created": "02/12/2021 16:54:00", "department": "Computing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-12-02", "gender": "female", "id": "f7f4d5d9-cd3c-4371-bc36-5a605864adf6", "open_date_time": "2021-11-2 16:48:32", "open_timestamp": 1638463712651, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "The Japanese Government announced today they're the first country to approve of Casirivimab/Imdevimab, a combination medicine, as a treatment for COVID-19.", "task_condition": "viz", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 328030, "what": "Japan approving a combination medicine for the treatment of COVID-19", "when_happened": "few_years_ago", "where_location": "Japan", "who": "Dr Osamu Okuda", "why": "Discusses information important to a large population of people, centres around healthcare and the curing of a global pandemic responsible for millions of deaths"}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_28", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-2 17:12:4", "close_timestamp": 1638465124039, "created": "02/12/2021 17:12:03", "department": "Computing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-12-02", "gender": "female", "id": "37f0914d-a25d-493c-800f-b15ce9fa8bf5", "open_date_time": "2021-11-2 16:54:23", "open_timestamp": 1638464063602, "summary": "It has been a ground breaking few days for US pharma giant Pfizer and their German partner BioNTech. Yesterday they announced the initiation of a BLA with the US Food and Drug Administration for the approval of their vaccine in persons aged 16 and over. This comes just three days after the announcement of their first quarter vaccine sales being up $3.5 billion, and two days after the monumental approval of vaccine use in children by Health Canada. Last month Pfizer extended vaccine trials to adolescents between the ages of 12 and 15 and positive results were reported on within only 6 days. Now, less than three weeks later, the vaccine is being rolled out for this age group in what can only be described as the first achievement of its kind.", "task_condition": "text", "task_key": "pfizer", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 1060437}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_28", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-2 17:29:6", "close_timestamp": 1638466146674, "created": "02/12/2021 17:29:06", "department": "Computing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-12-02", "gender": "female", "id": "ca2db376-5402-489c-bdad-0326fb9b0b8f", "open_date_time": "2021-11-2 17:12:15", "open_timestamp": 1638465135089, "summary": "In the wake of a lawsuit launched against Astrazeneca by the European Union, R-Pharm, a Russian drugmaker, will begin production of the vaccine for exports most likely to the Persian Gulf. Astrazeneca came under scrutiny in April when they were threatened with legal action by the EU for \"breaching contractual obligations to supply the product\". This feud came not long after another bout of criticism linked to their wrongful publishing of vaccine efficiency, with the figure changing from 79% to 76% within just days. The spreading of vaccine production will hopefully help the UK based big pharma company meet their contractual obligations going forward.", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "under_graduate_year_3", "time_taken_in_seconds": 1011585}}}